SLOTS-CAPITAL
11.6.2021 11:24:04 CEST | Business Wire | Pressemeddelelse
Slots Capital, et af de mest populære online casinoer i verden, er nu tilgængelig for flere spillere end nogensinde før, når de for første gang lander i flere nye lande.
Det betyder, at spillere i Belgien, Rumænien, Grækenland, Danmark, Finland, Irland, Letland og Luxembourg nu kan nyde godt af den førsteklasses online casinooplevelse, som Slots Capital tilbyder.
Hvis du elsker spillemaskiner, så er Slots Capital stedet, hvor du kan vælge mellem mere end 300 spil fra kendte udviklere såsom Rival, Saucify, Dragon og Qora.
Faktisk har vi for nylig styrket vores spillemaskiner og bordspil-lobby med titler fra eftertragtede spilstudier, herunder Rival Gaming, Dragon Gaming, Saucify Gaming og Qora Gaming.
Vi vil også tilføje spillemaskiner fra Arrow's Edge i de kommende uger, men i mellemtiden kan spillere prøve de nyeste titler ved at udforske vores lobby, som inkluderer:
- Dead Beats
- Irish Wishes
- Lucky Macau
- Panda Playtime
- Sands of Space
- Twin Dragons
- Viking Victory
- Win Another Day
- Wrath of Medusa
- Yeti Hunt i3D
Slots Capital er ikke kun kendt for at være den bedste destination for spillemaskiner, vores spillere elsker også de daglige bonusser, bonusser uden indbetaling, superhurtige udbetalinger og 24/7 kundesupport.
Vi er mobilvenlige, hvilket betyder, at du kan tilgå alle vores spillemaskiner samt vores generøse bonusser, betalingsmuligheder og kundesupport fra din smartphone eller tablet.
Hos Slots Capital vil vi gerne byde nye spillere velkommen med en enorm generøs indbetalingsmatchbonus; når du indbetaler 150 kr., tilføjer vi 450 kr. til din saldo, hvilket giver dig 600 kr. at spille med totalt.
Hvis ikke det var nok, tilbyder vi også match-bonusser på dine næste tre indbetalinger, hvor du kan modtage 250 %, 300 % og 400 %!
Sharon Kane, Slots Capital , udtalte: "Vi er så begejstrede over at have lanceret Slots Capital på otte nye markeder, og for at spillere kan nyde en af de bedste online casinooplevelser på markedet.
Vi har for nylig føjet en række efterspurgte udbydere til vores allerede imponerende lobby, hvilket viser vores engagement til at tilbyde spillere det bredest-mulige udvalg af spillemaskiner at vælge imellem.
Hvis du ikke allerede har spillet hos Slots Capital, hvad venter du så på - udnyt vores gavmilde velkomsttilbud og kom og se, hvad alle taler om."
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210611005178/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum